Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Incyte (Nasdaq:INCY) today announced the expansion of its Moments of Clarity program, which amplifies the voices of people livi...
Piper Sandler analyst Allison Bratzel maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $82 ...
Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today announced an exclusive opti...
Guggenheim analyst Michael Schmidt upgrades Incyte (NASDAQ:INCY) from Neutral to Buy and announces $125 price target.
RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $81...
Truist Securities analyst Srikripa Devarakonda reiterates Incyte (NASDAQ:INCY) with a Hold and raises the price target from ...
Wells Fargo analyst Derek Archila maintains Incyte (NASDAQ:INCY) with a Overweight and raises the price target from $89 to $97.
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its...
